UA78974C2 - Use of flibanserin for treating disorders of sexual desire - Google Patents

Use of flibanserin for treating disorders of sexual desire Download PDF

Info

Publication number
UA78974C2
UA78974C2 UA20040503697A UA20040503697A UA78974C2 UA 78974 C2 UA78974 C2 UA 78974C2 UA 20040503697 A UA20040503697 A UA 20040503697A UA 20040503697 A UA20040503697 A UA 20040503697A UA 78974 C2 UA78974 C2 UA 78974C2
Authority
UA
Ukraine
Prior art keywords
acid
sexual desire
flibanserin
sex drive
sexual
Prior art date
Application number
UA20040503697A
Other languages
English (en)
Ukrainian (uk)
Inventor
Kenneth Robert Evans
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of UA78974C2 publication Critical patent/UA78974C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UA20040503697A 2001-10-20 2002-04-10 Use of flibanserin for treating disorders of sexual desire UA78974C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01125020 2001-10-20
PCT/EP2002/011103 WO2003035072A1 (en) 2001-10-20 2002-10-04 Use of flibanserin in the treatment of sexual disorders

Publications (1)

Publication Number Publication Date
UA78974C2 true UA78974C2 (en) 2007-05-10

Family

ID=8179028

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20040503697A UA78974C2 (en) 2001-10-20 2002-04-10 Use of flibanserin for treating disorders of sexual desire

Country Status (31)

Country Link
US (9) US7151103B2 (enExample)
EP (2) EP1446122B1 (enExample)
JP (3) JP2005506370A (enExample)
KR (3) KR101235102B1 (enExample)
CN (4) CN102125557A (enExample)
AR (2) AR037109A1 (enExample)
AT (1) ATE327757T1 (enExample)
AU (1) AU2002333894B2 (enExample)
BR (1) BR0213358A (enExample)
CA (1) CA2458067C (enExample)
CY (1) CY1105082T1 (enExample)
DE (1) DE60211937T2 (enExample)
DK (1) DK1446122T5 (enExample)
EA (1) EA007274B1 (enExample)
EC (1) ECSP045069A (enExample)
ES (1) ES2266632T3 (enExample)
HR (1) HRP20040352B1 (enExample)
HU (1) HUP0401023A3 (enExample)
IL (2) IL160389A0 (enExample)
ME (1) MEP42808A (enExample)
MX (1) MXPA04003666A (enExample)
MY (1) MY127290A (enExample)
NO (1) NO325556B1 (enExample)
NZ (1) NZ532079A (enExample)
PL (1) PL208744B1 (enExample)
PT (1) PT1446122E (enExample)
RS (1) RS50876B (enExample)
SI (1) SI1446122T1 (enExample)
UA (1) UA78974C2 (enExample)
WO (1) WO2003035072A1 (enExample)
ZA (1) ZA200401366B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
JP2007516949A (ja) * 2003-07-16 2007-06-28 ファイザー・インク 性機能不全の治療
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
CA2580730C (en) 2003-09-25 2015-01-13 Cenomed, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
KR20070014184A (ko) * 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 성기능 장애 치료용 신규 약제학적 조성물 ⅱ
CA2566699C (en) 2004-05-11 2016-02-16 Emotional Brain B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
EP1789048A1 (en) * 2004-09-03 2007-05-30 Boehringer Ingelheim International GmbH Method for the treatment of attention deficit hyperactivity disorder
CA2599937A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
EP1858516A1 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International GmbH Pharmaceutical compositions for the treatment and/or prevention of depression
EP1904182A2 (en) * 2005-05-06 2008-04-02 Boehringer Ingelheim International GmbH Method for the treatment of drug abuse with flibanserin
CA2608363A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
CA2608713A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
CA2614833A1 (en) * 2005-07-12 2007-01-18 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 2, 3-disubstituted tropanes for the treatment of disorders of sexual desire
EP1912650B8 (en) 2005-08-03 2017-10-18 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US7923449B2 (en) 2005-10-29 2011-04-12 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP2233472B1 (en) * 2006-03-28 2014-01-15 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
RS54398B1 (sr) * 2006-05-09 2016-04-28 Sprout Pharmaceuticals, Inc. Upotreba flibanserina za lečenje poremećaja seksualne želje u postmenopauzi
CA2654798C (en) * 2006-06-30 2015-01-13 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
WO2008006838A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
WO2008006839A2 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900270A1 (ru) 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
WO2008074795A1 (en) 2006-12-20 2008-06-26 Boehringer Ingelheim International Gmbh Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
JP5087011B2 (ja) * 2007-01-23 2012-11-28 馨 井上 眼疾患モデル用非ヒト動物
JP2010522714A (ja) * 2007-03-28 2010-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な医薬組成物
UY31335A1 (es) * 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
DE102011012712A1 (de) 2011-03-01 2012-09-06 Frank Lehmann-Horn Verwendung von Aldosteron-Rezeptor-Antagonisten zur Behandlung von weiblicher sexueller Dysfunktion
WO2012140642A1 (en) 2011-04-10 2012-10-18 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
KR20230136142A (ko) * 2012-08-06 2023-09-26 에스원 바이오파머, 인크. 치료 방법
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017100324A1 (en) * 2015-12-10 2017-06-15 Repros Therapeutics Inc. Combination therapy for treating female hypoactive sexual desire disorders

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US479739A (en) * 1892-07-26 dimond
US3096248A (en) 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3406178A (en) 1964-02-04 1968-10-15 Monsanto Chem Australia Ltd Preparation of 2-substituted benzimidazoles
US3362956A (en) 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US4200641A (en) 1976-12-21 1980-04-29 Janssen Pharmaceutica, N.V. 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives
DK251079A (da) 1978-06-20 1979-12-21 Synthelabo Fremgangsmaade til fremstilling af phenylpiperazinderivater
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja) 1982-02-02 1983-08-10 Fujisawa Pharmaceut Co Ltd 医薬組成物
IT1176613B (it) 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
DE3620643A1 (de) 1985-06-22 1987-01-22 Sandoz Ag Thiazole, ihre herstellung und verwendung
HUT43600A (en) 1985-06-22 1987-11-30 Sandoz Ag Process for production of new thiazole derivatives and medical compound containing those
GB8601160D0 (en) 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
US5036088A (en) 1986-06-09 1991-07-30 Pfizer Inc. Antiallergy and antiinflammatory agents, compositions and use
JPH0784462B2 (ja) 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8830312D0 (en) 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
US4954503A (en) 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
WO1992002215A1 (en) 1990-08-09 1992-02-20 Massachusetts Institute Of Technology Method for treating the premenstrual or late luteal phase syndrome
CA2071488C (en) 1990-08-24 1996-05-07 Kazuto Kobayashi Base for film-coating pharmaceuticals and method for preparing same
NZ241613A (en) 1991-02-27 1993-06-25 Janssen Pharmaceutica Nv Highlighting intagliations in tablets
SE9100860D0 (sv) 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
FR2675800A1 (fr) 1991-04-26 1992-10-30 Rhone Poulenc Rorer Sa Derives heterocycliques antiserotonines leur preparation et les medicaments les contenant.
FI934894A0 (fi) 1991-05-07 1993-11-05 Merck & Co Inc Fibrinogenreceptorantagonister
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
DE4216364A1 (de) 1991-12-14 1993-11-25 Thomae Gmbh Dr K Neue Pyridylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5225417A (en) 1992-01-21 1993-07-06 G. D. Searle & Co. Opioid agonist compounds
US5492907A (en) 1992-12-09 1996-02-20 The United States Of America As Represented By The Department Of Health & Human Services Antipsychotic composition and method of treatment
JP3204510B2 (ja) 1993-04-05 2001-09-04 コンペティティブ テクノロジーズ,インク. 勃起不全の診断および治療
FR2707294B1 (fr) 1993-07-06 1995-09-29 Pf Medicament Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
CA2192975C (en) 1994-06-14 1999-09-21 Anton F. Fliri Benzimidazolone derivatives
JP3874793B2 (ja) 1994-08-23 2007-01-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー イブプロフェンおよびコデイン含有の改良された医薬処方
DE69531476T2 (de) 1994-09-12 2004-06-09 Lilly Industries Ltd., Basingstoke Serotonergische Modulatoren
JPH08143476A (ja) 1994-11-18 1996-06-04 Japan Tobacco Inc 薬物放出制御膜及び固形製剤
FR2727682A1 (fr) 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5883094A (en) 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
US5854290A (en) 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
US6083947A (en) * 1996-01-29 2000-07-04 The Regents Of The University Of California Method for treating sexual dysfunctions
GB9613423D0 (en) 1996-06-26 1996-08-28 Lilly Industries Ltd Pharmaceutical compounds
US5916916A (en) 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
ATE271379T1 (de) 1996-11-06 2004-08-15 Wockhardt Europ Ltd System zur verzögerten freisetzung säurelabiler substanzen
AU731349B2 (en) 1996-12-02 2001-03-29 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating sexual dysfunctions
US5859246A (en) 1997-01-30 1999-01-12 Neurogen Corporation 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
GB9706089D0 (en) 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US20040023948A1 (en) 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
DE69826660T2 (de) 1997-06-11 2005-10-06 The Procter & Gamble Company, Cincinnati Filmüberzogene tablette für verbesserte verträglichkeit im oberen magen-darmtrakt
DE69815003T2 (de) 1997-09-10 2004-04-01 Takeda Chemical Industries, Ltd. Stabilisierte pharmazeutische Zusammensetzung
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
CH692199A8 (fr) 1997-10-09 2002-06-14 Cermol S.A. Composes pyridiques et compositions pharmaceutique
JP3724157B2 (ja) 1997-10-30 2005-12-07 コニカミノルタホールディングス株式会社 映像観察装置
FR2775188B1 (fr) 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
WO1999059584A1 (en) 1998-05-20 1999-11-25 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
JP2002515435A (ja) 1998-05-21 2002-05-28 イーライ・リリー・アンド・カンパニー 鬱病処置のための組合せ治療
US20020151543A1 (en) 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
JP2002517444A (ja) 1998-06-11 2002-06-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作動薬としてのスピロピペリジン誘導体
US6068846A (en) 1998-08-05 2000-05-30 Melaleuca, Incorporated Methods and materials for treating depression and mood disorder
EP0982030A3 (en) 1998-08-17 2000-05-10 Pfizer Products Inc. 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
WO2000028993A1 (en) * 1998-11-19 2000-05-25 Nortran Pharmaceuticals, Inc. Serotonin ligands as pro-erectile compounds
US6680071B1 (en) 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
WO2000063193A1 (en) 1999-04-16 2000-10-26 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
CN1461216A (zh) 1999-04-28 2003-12-10 呼吸器有限公司 用作治疗有关支气管收缩的机能障碍的药物的化合物
IT1312310B1 (it) 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US20030055070A1 (en) 1999-07-01 2003-03-20 Wilma Harrison Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
US6346548B1 (en) 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
DE19961334A1 (de) 1999-12-17 2001-06-21 Roehm Gmbh Spritzgußverfahren für neutrale und säuregruppenhaltige (Meth)acrylat-Copolymere
CN1396829A (zh) 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
IL152781A0 (en) 2000-06-28 2003-06-24 Pfizer Prod Inc Melanocortin receptor ligands
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US20020052370A1 (en) 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6521623B1 (en) 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
ES2273891T3 (es) 2000-09-19 2007-05-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Nuevos derivados de bencimidazolona que presentan actividad en los receptores de serotonina y dopamina.
WO2002024661A2 (en) 2000-09-19 2002-03-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
AU2002226895B2 (en) 2000-11-22 2006-10-12 Abbott Laboratories Selective dopamine D4 receptor agonists for treating sexual dysfunction
GB0105893D0 (en) 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
GB0106446D0 (en) 2001-03-15 2001-05-02 Vernalis Res Ltd Chemical compounds
CN1243723C (zh) 2001-03-28 2006-03-01 辉瑞大药厂 作为fsad的nep抑制剂的n-苯丙基环戊基取代的戊二酰胺衍生物
PT1256343E (pt) 2001-05-11 2006-11-30 Jurgen K Beck Flibaserina para o tratamento de perturbações do movimento extrapiramidais
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US7115628B2 (en) 2001-07-18 2006-10-03 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
CA2455987C (en) 2001-07-30 2010-06-29 Neotherapeutics, Inc. Tetrahydroindolone and purine derivatives linked to arylpiperazines
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
RS50742B (sr) 2001-08-02 2010-08-31 Bidachem S.P.A. Stabilni polimorf flibanserina, postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
DE10138273A1 (de) 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
US20030060475A1 (en) 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
HUP0202719A3 (en) 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
DE10209982A1 (de) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
EP1511489B1 (en) 2002-05-22 2011-03-02 Boehringer Ingelheim Pharma GmbH & Co.KG New pharmaceutical compositions containing flibanserin polymorph a
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
WO2004010932A2 (en) 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
US20040132697A1 (en) 2002-11-06 2004-07-08 Pfizer Inc. Treatment of female sexual dysfunction
GB0225908D0 (en) 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US20040193452A1 (en) 2003-01-06 2004-09-30 Laura Berman Method and system for computerized sexual function assessment of female users
WO2004069339A1 (en) 2003-01-29 2004-08-19 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
US20050037983A1 (en) 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
US20050065158A1 (en) 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
JP2007516949A (ja) 2003-07-16 2007-06-28 ファイザー・インク 性機能不全の治療
EP1510133A1 (en) * 2003-09-01 2005-03-02 Belovo S.A., Egg Science & Technology Balanced oil composition
CA2537837A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
WO2005044238A1 (en) 2003-11-07 2005-05-19 Ranbaxy Laboratories Limited Modified release solid dosage form of amphetamine salts
US20050239798A1 (en) 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
KR20070014184A (ko) 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 성기능 장애 치료용 신규 약제학적 조성물 ⅱ
US20060014757A1 (en) 2004-07-14 2006-01-19 Boehringer Ingelheim Pharmaceuticals Method for the treatment of anorexia nervosa
US20060025420A1 (en) 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
EP1789048A1 (en) 2004-09-03 2007-05-30 Boehringer Ingelheim International GmbH Method for the treatment of attention deficit hyperactivity disorder
JP2008516909A (ja) 2004-10-18 2008-05-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 前立腺及び下部泌尿生殖路の病気を治療するためのβ−3アゴニストの使用
CA2599937A1 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
EP1858516A1 (en) 2005-03-04 2007-11-28 Boehringer Ingelheim International GmbH Pharmaceutical compositions for the treatment and/or prevention of depression
EP1904182A2 (en) 2005-05-06 2008-04-02 Boehringer Ingelheim International GmbH Method for the treatment of drug abuse with flibanserin
US20060258640A1 (en) 2005-05-13 2006-11-16 Boehringer Ingelheim International Gmbh Use of Flibanserin in the treatment of chronic pain
CA2608363A1 (en) 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
CA2608713A1 (en) 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
KR101306635B1 (ko) 2005-06-27 2013-10-11 밸리언트 인터내셔널(바베이도스) 에스알엘 부프로피온염의 개질-방출 제형
EP1912650B8 (en) 2005-08-03 2017-10-18 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
WO2007022325A2 (en) 2005-08-16 2007-02-22 Wionics Research Packet detection
HU227490B1 (en) 2005-08-26 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sustained release pharmaceutical preparation containing carvedilol
EP1940357A2 (en) 2005-09-30 2008-07-09 SmithKline Beecham Corporation Pharmaceutical compositions
US7923449B2 (en) 2005-10-29 2011-04-12 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
BRPI0707325A2 (pt) 2006-01-27 2011-05-03 Eurand Inc formulação de dosagem de liberação multiparticulada e método para preparação da mesma
WO2007093624A2 (en) 2006-02-18 2007-08-23 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
EP1988897A1 (en) 2006-02-20 2008-11-12 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of urinary incontinence
US20090247546A1 (en) 2006-02-28 2009-10-01 Boehringer Ingelheim International Gmbh Treatment of Prevention of Valvular Heart Disease with Flibanserin
RS54398B1 (sr) 2006-05-09 2016-04-28 Sprout Pharmaceuticals, Inc. Upotreba flibanserina za lečenje poremećaja seksualne želje u postmenopauzi
CA2654798C (en) 2006-06-30 2015-01-13 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
WO2008006839A2 (en) 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments
WO2008006838A1 (en) 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900270A1 (ru) 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления
WO2008074795A1 (en) 2006-12-20 2008-06-26 Boehringer Ingelheim International Gmbh Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
JP2010522714A (ja) 2007-03-28 2010-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な医薬組成物
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts

Also Published As

Publication number Publication date
ZA200401366B (en) 2005-01-26
PT1446122E (pt) 2006-08-31
PL208744B1 (pl) 2011-06-30
ATE327757T1 (de) 2006-06-15
US7151103B2 (en) 2006-12-19
US20170100392A1 (en) 2017-04-13
CN102058597A (zh) 2011-05-18
NZ532079A (en) 2007-03-30
US9782403B2 (en) 2017-10-10
EA007274B1 (ru) 2006-08-25
IL160389A0 (en) 2004-07-25
BR0213358A (pt) 2004-10-26
ES2266632T3 (es) 2007-03-01
KR101235102B1 (ko) 2013-02-20
AU2002333894B2 (en) 2007-11-01
HUP0401023A3 (en) 2004-10-28
MY127290A (en) 2006-11-30
US10098876B2 (en) 2018-10-16
NO325556B1 (no) 2008-06-16
JP2007131631A (ja) 2007-05-31
US9468639B2 (en) 2016-10-18
PL367358A1 (en) 2005-02-21
KR20040047931A (ko) 2004-06-05
CN101347431A (zh) 2009-01-21
MXPA04003666A (es) 2004-07-22
WO2003035072A1 (en) 2003-05-01
US20140057923A1 (en) 2014-02-27
AR037109A1 (es) 2004-10-20
CA2458067A1 (en) 2003-05-01
US8227471B2 (en) 2012-07-24
KR20110132479A (ko) 2011-12-07
EP1674102A1 (en) 2006-06-28
DK1446122T5 (da) 2006-08-14
MEP42808A (en) 2011-05-10
US20130096137A1 (en) 2013-04-18
AR077480A2 (es) 2011-08-31
DE60211937D1 (de) 2006-07-06
US20070072872A1 (en) 2007-03-29
US20030104980A1 (en) 2003-06-05
RS50876B (sr) 2010-08-31
CY1105082T1 (el) 2010-03-03
IL160389A (en) 2010-05-31
US20180055839A1 (en) 2018-03-01
DK1446122T3 (da) 2006-07-03
EP1446122B1 (en) 2006-05-31
KR20090130196A (ko) 2009-12-18
JP2005506370A (ja) 2005-03-03
HRP20040352A2 (en) 2005-02-28
US10307420B2 (en) 2019-06-04
DE60211937T2 (de) 2006-12-28
YU30004A (sh) 2006-08-17
ECSP045069A (es) 2004-05-28
EA200400481A1 (ru) 2004-10-28
HRP20040352B1 (en) 2012-02-29
NO20041588L (no) 2004-04-19
US20150011563A1 (en) 2015-01-08
CA2458067C (en) 2009-02-10
CN102125557A (zh) 2011-07-20
US20150342948A1 (en) 2015-12-03
HUP0401023A2 (hu) 2004-08-30
US20190000842A1 (en) 2019-01-03
JP2012067134A (ja) 2012-04-05
CN1571670A (zh) 2005-01-26
SI1446122T1 (sl) 2006-10-31
EP1446122A1 (en) 2004-08-18

Similar Documents

Publication Publication Date Title
UA78974C2 (en) Use of flibanserin for treating disorders of sexual desire
RU2384333C2 (ru) Применение флибансерина для лечения предменструальных и иных сексуальных расстройств у женщин
DK2021006T3 (en) USE OF flibanserin in postmenopausal SEXLYSTFORSTYRRELSER
KR101436793B1 (ko) 폐경전 성욕 장애의 치료를 위한 플리반세린의 용도
JP2008506688A (ja) 神経性無食欲症の治療方法
JP2008540672A (ja) 病状に起因する性的機能不全の治療方法
JP2008511569A (ja) 注意欠如活動過多障害の治療方法
CN101801380B (zh) 血管舒缩症状的制药用途
AU2005231479A1 (en) (R,R)-formoterol in combination with other pharmacological agents
US10675280B2 (en) Treating sexual desire disorders with flibanserin
JP2010518040A (ja) 不眠症を治療するためのフリバンセリンの使用
HK1131059A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
CN101304746A (zh) 氟班色林在治疗绝经前性欲障碍中的用途
HK1157678A (zh) 弗利班西林在治疗性障碍中的用途
CN101443011A (zh) 氟班色林于治疗绝经后性欲障碍的用途
HK1126972A (en) Use of flibanserin in the treatment of sexual disorders
HK1124266A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders